Eye Diseases Clinical Trials

29 recruitingLast updated: June 18, 2026

There are 29 actively recruiting eye diseases clinical trials across 20 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Miami, Florida, United States, London, United Kingdom, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Eye Diseases Trials at a Glance

29 actively recruiting trials for eye diseases are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Miami, London, and Ann Arbor. Lead sponsors running eye diseases studies include Laboratoires Thea, Duke University, and National Eye Institute (NEI).

Browse eye diseases trials by phase

Treatments under study

About Eye Diseases Clinical Trials

Looking for clinical trials for Eye Diseases? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Eye Diseases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Eye Diseases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting

The Proactive Ophthalmic Examination Cohort

Eye DiseasesVision Impairment
Zhongshan Ophthalmic Center, Sun Yat-sen University5,000 enrolled1 locationNCT05851287
Recruiting

Screening for Research Participants

Eye Diseases
National Eye Institute (NEI)10,000 enrolled1 locationNCT00655096
Recruiting
Phase 3

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Sensation DisordersLeber Congenital AmaurosisRetinal Disease+7 more
Laboratoires Thea32 enrolled16 locationsNCT06891443
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting
Phase 3

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

Eye DiseasesMacular Degeneration, WetSub-Macular Hemorrhage
King's College Hospital NHS Trust210 enrolled36 locationsNCT04663750
Recruiting

Adaptive Optics Retinal Imaging

Healthy VolunteersEye Diseases
National Eye Institute (NEI)1,000 enrolled1 locationNCT02317328
Recruiting
Not Applicable

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

GlaucomaEye DiseasesCornea Disease
Centre hospitalier de l'Université de Montréal (CHUM)20 enrolled1 locationNCT04232982
Recruiting

Natural History Study of Patients With EYS-Associated RP

Retinitis PigmentosaEye Diseases
Sensor Technology for Deafblind45 enrolled1 locationNCT07228793
Recruiting
Not Applicable

RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

TrachomaEye DiseasesTrichiasis
University of North Carolina, Chapel Hill1,000 enrolled2 locationsNCT07322302
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Not Applicable

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

Retinal DiseaseGlaucomaOptic Nerve Diseases+1 more
Duke University50 enrolled1 locationNCT06841575
Recruiting

Assessment of the Ocular Microbiome in Health and Disease

Microbial ColonizationEye DiseasesOphthalmopathy
Vanderbilt University Medical Center500 enrolled1 locationNCT05414994
Recruiting
Phase 2

SGLT2 Inhibitors in Geographic Atrophy

Geographic AtrophyRetinal diseasesRetinal Degeneration+2 more
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Not Applicable

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

GlaucomaEye DiseasesVisual Impairment
University of Michigan900 enrolled1 locationNCT06934577
Recruiting
Phase 4

Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work

Dry EyeEye DiseasesEyes Dry Chronic
Southern College of Optometry40 enrolled3 locationsNCT07266948
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting

Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging

Eye Diseases
Duke University42 enrolled1 locationNCT06177639
Recruiting
Phase 1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Retinitis PigmentosaMacular DegenerationDiabetic Retinopathy+3 more
The Foundation for Orthopaedics and Regenerative Medicine20 enrolled2 locationsNCT05147701
Recruiting
Phase 1

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826
Recruiting
Phase 2Phase 3

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid DiseasesEndocrine System DiseasesThyroid Eye Disease+9 more
Sling Therapeutics, Inc.75 enrolled2 locationsNCT06112340